Vivus (NASDAQ:VVUS)’s share price dropped 4.1% during mid-day trading on Wednesday . The company traded as low as $0.48 and last traded at $0.51. Approximately 15,458 shares changed hands during trading, a decline of 98% from the average daily volume of 729,483 shares. The stock had previously closed at $0.49.
Separately, ValuEngine upgraded Vivus from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd.
The company has a debt-to-equity ratio of -24.71, a current ratio of 6.80 and a quick ratio of 6.34. The stock has a market capitalization of $55.03 million, a PE ratio of -1.66 and a beta of 0.56.
Vivus (NASDAQ:VVUS) last issued its quarterly earnings data on Tuesday, May 8th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.11) by $0.01. Vivus had a negative return on equity of 843.43% and a negative net margin of 46.67%. The company had revenue of $11.90 million during the quarter. equities analysts forecast that Vivus will post -0.45 EPS for the current fiscal year.
A hedge fund recently raised its stake in Vivus stock. Creative Planning boosted its holdings in Vivus (NASDAQ:VVUS) by 1,691.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 366,706 shares of the biopharmaceutical company’s stock after purchasing an additional 346,235 shares during the quarter. Creative Planning owned about 0.35% of Vivus worth $184,000 at the end of the most recent quarter. 23.73% of the stock is currently owned by institutional investors.
VIVUS, Inc, a biopharmaceutical company, develops and commercializes novel therapeutic products to address unmet medical needs in human health in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or obese patients, or 27 or greater, or overweight patients in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction.
Receive News & Ratings for Vivus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivus and related companies with MarketBeat.com's FREE daily email newsletter.